Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Visual benefit versus visual gain: what is the effect of baseline covariants in the treatment arm relative to the control arm? A pooled analysis of ANCHOR and MARINA.

Tufail A, Margaron P, Guerin T, Larsen M.

Br J Ophthalmol. 2019 Sep 27. pii: bjophthalmol-2018-313682. doi: 10.1136/bjophthalmol-2018-313682. [Epub ahead of print]

2.

Systemic Safety in Ranibizumab-Treated Patients with Neovascular Age-Related Macular Degeneration: A Patient-Level Pooled Analysis.

Zarbin MA, Francom S, Grzeschik S, Tuomi L, Haskova Z, Macfadden W, Margaron P, Snow H, Cruess A, Staurenghi G, Dunger-Baldauf C.

Ophthalmol Retina. 2018 Nov;2(11):1087-1096. doi: 10.1016/j.oret.2018.04.018. Epub 2018 Jun 11.

PMID:
31047547
3.

Dose-response analysis of ranibizumab as-needed regimens for visual improvement in patients with diabetic macular edema using a modelling approach.

Xiong Y, Pigeolet E, Mulyukov Z, Margaron P, Racine A, Clemens A.

Contemp Clin Trials. 2019 May;80:34-39. doi: 10.1016/j.cct.2019.03.008. Epub 2019 Mar 21.

4.

Efficacy and safety of ranibizumab monotherapy versus ranibizumab in combination with verteporfin photodynamic therapy in patients with polypoidal choroidal vasculopathy: 12-month outcomes in the Japanese cohort of EVEREST II study.

Takahashi K, Ohji M, Terasaki H, Honda S, Margaron P, Guerin T, Yuzawa M.

Clin Ophthalmol. 2018 Sep 13;12:1789-1799. doi: 10.2147/OPTH.S171015. eCollection 2018.

5.

MACUSTAR: Development and Clinical Validation of Functional, Structural, and Patient-Reported Endpoints in Intermediate Age-Related Macular Degeneration.

Finger RP, Schmitz-Valckenberg S, Schmid M, Rubin GS, Dunbar H, Tufail A, Crabb DP, Binns A, Sánchez CI, Margaron P, Normand G, Durbin MK, Luhmann UFO, Zamiri P, Cunha-Vaz J, Asmus F, Holz FG; on behalf of the MACUSTAR consortium.

Ophthalmologica. 2019;241(2):61-72. doi: 10.1159/000491402. Epub 2018 Aug 28. Review.

6.

Ranibizumab in Diabetic Macular Oedema - A Benefit-risk Analysis of Ranibizumab 0.5 mg PRN Versus Laser Treatment.

Ziemssen F, Cruess A, Dunger-Baldauf C, Margaron P, Snow H, Strain WD.

Eur Endocrinol. 2017 Aug;13(2):91-98. doi: 10.17925/EE.2017.13.02.91. Epub 2017 Aug 22.

7.

Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial.

Koh A, Lai TYY, Takahashi K, Wong TY, Chen LJ, Ruamviboonsuk P, Tan CS, Feller C, Margaron P, Lim TH, Lee WK; EVEREST II study group.

JAMA Ophthalmol. 2017 Nov 1;135(11):1206-1213. doi: 10.1001/jamaophthalmol.2017.4030.

8.

Vascular Safety of Ranibizumab in Patients With Diabetic Macular Edema: A Pooled Analysis of Patient-Level Data From Randomized Clinical Trials.

Zarbin MA, Dunger-Baldauf C, Haskova Z, Koovejee P, Mousseau MC, Margaron P, Snow H, Beaumont PE, Staurenghi G, Francom S.

JAMA Ophthalmol. 2017 May 1;135(5):424-431. doi: 10.1001/jamaophthalmol.2017.0455.

9.

Baseline visual acuity strongly predicts visual acuity gain in patients with diabetic macular edema following anti-vascular endothelial growth factor treatment across trials.

Dugel PU, Hillenkamp J, Sivaprasad S, Vögeler J, Mousseau MC, Wenzel A, Margaron P, Hashmonay R, Massin P.

Clin Ophthalmol. 2016 Jun 14;10:1103-10. doi: 10.2147/OPTH.S100764. eCollection 2016.

10.

Epidemiological and Clinical Baseline Characteristics as Predictive Biomarkers of Response to Anti-VEGF Treatment in Patients with Neovascular AMD.

Tsilimbaris MK, López-Gálvez MI, Gallego-Pinazo R, Margaron P, Lambrou GN.

J Ophthalmol. 2016;2016:4367631. doi: 10.1155/2016/4367631. Epub 2016 Mar 17. Review.

11.

Predictive Value of Retinal Morphology for Visual Acuity Outcomes of Different Ranibizumab Treatment Regimens for Neovascular AMD.

Waldstein SM, Wright J, Warburton J, Margaron P, Simader C, Schmidt-Erfurth U.

Ophthalmology. 2016 Jan;123(1):60-9. doi: 10.1016/j.ophtha.2015.09.013. Epub 2015 Oct 17.

PMID:
26481821
12.

Apolipoprotein B100 secretion by cultured ARPE-19 cells is modulated by alteration of cholesterol levels.

Wu T, Fujihara M, Tian J, Jovanovic M, Grayson C, Cano M, Gehlbach P, Margaron P, Handa JT.

J Neurochem. 2010 Sep;114(6):1734-44. doi: 10.1111/j.1471-4159.2010.06884.x. Epub 2010 Jul 27.

13.

Evaluation of 9-cis-retinyl acetate therapy in Rpe65-/- mice.

Maeda T, Maeda A, Casadesus G, Palczewski K, Margaron P.

Invest Ophthalmol Vis Sci. 2009 Sep;50(9):4368-78. doi: 10.1167/iovs.09-3700. Epub 2009 Apr 30.

14.

Comparing pegaptanib and triamcinolone efficacy in the rat choroidal neovascularization model.

Criswell MH, Hu WZ, Steffens TJ, Li R, Margaron P.

Arch Ophthalmol. 2008 Jul;126(7):946-52. doi: 10.1001/archopht.126.7.946.

PMID:
18625941
15.

Photodynamic therapy with verteporfin in a rabbit model of corneal neovascularization.

Holzer MP, Solomon KD, Vroman DT, Sandoval HP, Margaron P, Kasper TJ, Crosson CE.

Invest Ophthalmol Vis Sci. 2003 Jul;44(7):2954-8.

PMID:
12824237
16.

Status of therapies in development for the treatment of age-related macular degeneration.

Hunt DW, Margaron P.

IDrugs. 2003 May;6(5):464-9. Review.

PMID:
12789601
17.

Rapid induction of apoptosis in human keratinocytes with the photosensitizer QLT0074 via a direct mitochondrial action.

Li R, Bounds DJ, Granville D, Ip SH, Jiang H, Margaron P, Hunt DW.

Apoptosis. 2003 Jun;8(3):269-75.

PMID:
12766487
18.

Mitochondrial release of apoptosis-inducing factor and cytochrome c during smooth muscle cell apoptosis.

Granville DJ, Cassidy BA, Ruehlmann DO, Choy JC, Brenner C, Kroemer G, van Breemen C, Margaron P, Hunt DW, McManus BM.

Am J Pathol. 2001 Jul;159(1):305-11.

19.

Benzoporphyrin derivative monacid ring A (Verteporfin) alone has no inhibitory effect on intimal hyperplasia: in vitro and in vivo results.

Turnbull RG, Chen JC, Labow RS, Margaron P, Hsiang YN.

J Invest Surg. 2000 May-Jun;13(3):153-9.

PMID:
10933111
20.

Reduced xenograft rejection in rat striatum after pretransplant photodynamic therapy of murine neural xenografts.

Honey CR, Obochi MO, Shen H, Margaron P, Yip S, Levy JG.

J Neurosurg. 2000 Jan;92(1):127-31.

PMID:
10616091
21.

Release of cytochrome c, Bax migration, Bid cleavage, and activation of caspases 2, 3, 6, 7, 8, and 9 during endothelial cell apoptosis.

Granville DJ, Shaw JR, Leong S, Carthy CM, Margaron P, Hunt DW, McManus BM.

Am J Pathol. 1999 Oct;155(4):1021-5.

22.

Photodynamic therapy inhibits cell adhesion without altering integrin expression.

Margaron P, Sorrenti R, Levy JG.

Biochim Biophys Acta. 1997 Dec 12;1359(3):200-10.

24.

Structure-photodynamic activity relationships of a series of 4-substituted zinc phthalocyanines.

Margaron P, Grégoire MJ, Scasnár V, Ali H, van Lier JE.

Photochem Photobiol. 1996 Feb;63(2):217-23.

PMID:
8657735
25.

Evaluation of a 99mTc-antimyosin kit for myocardial infarct imaging.

Rousseau J, Sikorska HM, Gervais A, Bisson G, Margaron P, Lamoureux G, Mirza SA, van Lier JE.

J Nucl Biol Med. 1994 Dec;38(4 Suppl 1):43-53.

PMID:
7632767
26.

Phthalocyanine-induced photohemolysis: structure-activity relationship and the effect of fluoride.

Ben-Hur E, Malik Z, Dubbelman TM, Margaron P, Ali H, van Lier JE.

Photochem Photobiol. 1993 Sep;58(3):351-5.

PMID:
8234468
27.

Photodynamic properties of naphthosulfobenzoporphyrazines, novel asymmetric, amphiphilic phthalocyanine derivatives.

Margaron P, Langlois R, van Lier JE, Gaspard S.

J Photochem Photobiol B. 1992 Jul 15;14(3):187-99.

PMID:
1432390
28.

Mixed acenannellated metallotetraazaporphins: a new class of amphiphilic photosensitizers for the photodynamic therapy of cancer.

Gaspard S, Margaron P, Tempête C, Thi TH.

J Photochem Photobiol B. 1990 Mar;4(4):419-23.

PMID:
2111386

Supplemental Content

Loading ...
Support Center